How gut bacteria affect cancer treatment effectiveness
Improvement of cellular immunotherapy during dysbiosis- Resubmission
This study is looking at how changes in gut bacteria caused by antibiotics might affect the success of cancer treatments for melanoma, and it's especially for patients with advanced melanoma who have taken antibiotics.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of Arkansas for Med Scis NIH-funded |
| Lab location | 1 site (Little Rock, United States) |
| Project ID | NIH-10916290 on NIH RePORTER |
What this research studies
This research investigates the impact of antibiotic-induced changes in gut bacteria, known as dysbiosis, on the effectiveness of cellular immunotherapy for melanoma patients. The study aims to understand how these changes in the gut microbiome can influence the immune response to cancer treatments. By focusing on the relationship between dysbiosis and the tumor microenvironment, the researchers hope to develop strategies to enhance the efficacy of immunotherapy. Patients with advanced melanoma who have undergone antibiotic treatment may particularly benefit from this research.
Who could benefit from this research
Good fit: Ideal candidates for this research are melanoma patients who have received antibiotics and are undergoing or considering cellular immunotherapy.
Not a fit: Patients who have not received antibiotics or those with early-stage melanoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved outcomes for melanoma patients receiving cellular immunotherapy by addressing the negative effects of dysbiosis.
How similar studies have performed: Other research has shown promising results in understanding the role of the gut microbiome in cancer treatment, suggesting that this approach could yield significant insights.
Where this research is happening
Little Rock, United States
- Univ of Arkansas for Med Scis — Little Rock, United States (Active)
Researchers
- Principal investigator: Dings, Ruud P.m. — Univ of Arkansas for Med Scis
- Study coordinator: Dings, Ruud P.m.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.